Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Palatin Technologies, Inc. Common Stock
(NY:
PTN
)
23.00
+1.01 (+4.59%)
Official Closing Price
Updated: 8:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Palatin Technologies, Inc. Common Stock
< Previous
1
2
3
4
5
Next >
Palatin Technologies Scores Triple Win with Breakthrough Results in Obesity, Colitis, and Kidney Disease
April 10, 2025
Palatin Technologies Scores Triple Win with Breakthrough Results in Obesity, Colitis, and Kidney Disease
Via
News Direct
Palatin Technologies’ UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)
March 31, 2025
Via
AB Newswire
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight
↗
March 31, 2025
Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing.
Via
Benzinga
Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)
March 31, 2025
Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)
Via
News Direct
Earnings Scheduled For February 13, 2025
↗
February 13, 2025
Via
Benzinga
A Look Ahead: Palatin Techs's Earnings Forecast
↗
November 13, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
↗
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Earnings Preview: Palatin Techs
↗
February 14, 2024
Via
Benzinga
Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus
↗
March 28, 2025
Palatin's PL8177 showed promising ulcerative colitis trial results, with strong clinical response rates. FDA granted orphan status to its obesity drug PL7737.
Via
Benzinga
Palatin Technologies’ Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN)
March 27, 2025
Via
AB Newswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 25, 2025
Via
Benzinga
On Friday, there are stocks with unusual volume. Let's take a look.
↗
February 07, 2025
Unusual volume stocks in Friday's session
Via
Chartmill
Thursday's session: top gainers and losers
↗
February 06, 2025
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Get insights into the top gainers and losers of Monday's after-hours session.
↗
February 03, 2025
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
10 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
October 14, 2024
Via
Benzinga
Earnings Scheduled For November 14, 2024
↗
November 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
September 27, 2024
Via
Benzinga
Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions
August 29, 2024
Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions
Via
News Direct
PTN Stock Earnings: Palatin Techs Misses EPS for Q3 2024
↗
May 15, 2024
PTN stock results show that Palatin Techs missed analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
↗
April 12, 2024
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested...
Via
Benzinga
Topics
Stocks
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
↗
April 08, 2024
Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically significant efficacy in pain reduction and secondary symptoms. PL9643...
Via
Benzinga
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
February 28, 2024
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
February 28, 2024
Via
Benzinga
Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock Plummets
↗
February 28, 2024
Palatin Technologies' results from PL9643 MELODY-1 Phase 3 trial for dry eye disease. The co-primary endpoints and secondary endpoints did not reach statistical significance.
Via
Benzinga
Dow Dips 200 Points; TJX Posts Upbeat Sales
↗
February 28, 2024
U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.52% to 38,770.83 while the NASDAQ...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 28, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
February 15, 2024
Via
Benzinga
The 3 Best Penny Stocks to Buy in February 2024
↗
February 15, 2024
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.
Via
InvestorPlace
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
↗
February 01, 2024
Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
